A phase 2a study to investigate the effect of a single dose of migalastat HCl, a pharmacological chaperone, on agalsidase activity in subjects with Fabry disease

David Warnock, Daniel Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mark Thomas, Francois Eyskens, Suma Shankar, Majed Dasouki, Franklin Johnson, Pol Boudes, University of Alabama at Birmingham, Birmingham, AL, USA, Hopital du Sacre-Coeur, Montreal, QC, Canada, University of Iowa Children's Hospital, Iowa City, IA, USA, O&O Alpan, LLC, Springfield, VA, USA, Royal Melbourne Hospital, Parkville, Australia, Linear Clinical Research, Perth WA, Australia, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Emory University, Decatur, GA, USA, University of Kansas, Kansas City, KS, USA, Amicus Therapeutics, Cranbury, NJ, USA